2008Zhongguo jiceng yiyaoRequires access

A randomized and double-blind comparison with reboxetine and citalopram in patients with retardant depressive disorder

Wei-dong Cong

Open publisher page 0 citations

Abstract

Objective To study the efficacy and safety of reboxetine and citalopram in treating retardant depression.Methods A total of 59 patients with retardant depression were randomly divided into reboxetine group(n=29)and citalopram group(n=30)for the treatment of 6 weeks.The patients were assessed with the Hamilton depression scale(HAMD)and treatment emergent symptom scale(TESS).Results At the end of 6 weeks,the total scores of HAMD in reboxetine(18.48±6.38)group and citalopram(11.60±4.46)group both significantly decreased(P<0.001).Between two groups,the efficacy(82.8% and 56.7%)had significant differences(P<0.05)but side effects had no statistical significance.Conclusion Reboxetine has significant curative efficacy,milder adverse effects and higher safety for treating patients with retardant depression. Key words: Reboxetine; Citalopram; Depression

About this research paper

What this paper is about

Objective To study the efficacy and safety of reboxetine and citalopram in treating retardant depression.Methods A total of 59 patients with retardant depression were randomly divided into reboxetine group(n=29)and citalopram group(n=30)for the treatment of 6 weeks.The patients were assessed with the Hamilton depression scale(HAMD)and treatment emergent symptom scale(TESS).Results At the end of 6 weeks,the total scores of HAMD in reboxetine(18.48±6.38)group and citalopram(11.60±4.46)group both significantly decreased(P<0.001).Between two groups,the efficacy(82.8% and 56.7%)had significant differences(P<0.05)but side effects had no statistical significance.Conclusion Reboxetine has significant curative efficacy,milder adverse effects and higher safety for treating patients with retardant depression. Key words: Reboxetine; Citalopram; Depression

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To study the efficacy and safety of reboxetine and citalopram in treating retardant depression.Methods A total of 59 patients with retardant depression were randomly divided into reboxetine group(n=29)and citalopram group(n=30)for the treatment of 6 weeks.The patients were assessed with the Hamilton depression scale(HAMD)and treatment emergent symptom scale(TESS).Results At the end of 6 weeks,the total scores of HAMD in reboxetine(18.48±6.38)group and citalopram(11.60±4.46)group both significantly decreased(P<0.001).Between two groups,the efficacy(82.8% and 56.7%)had significant differences(P<0.05)but side effects had no statistical significance.Conclusion Reboxetine has significant curative efficacy,milder adverse effects and higher safety for treating patients with retardant depression. Key words: Reboxetine; Citalopram; Depression

Key concepts: Reboxetine, Hamd, Citalopram, Medicine, Depression (economics), Major depressive disorder, Adverse effect, Anesthesia

Related papers

Back to paper searchBrowse research topicsOriginal source
A randomized and double-blind comparison with reboxetine and citalopram in patients with retardant depressive disorder — Research Paper | ScholarLens